Claudio D'Angelo (Spex Capital)
Overview
Claudio D’Angelo is a renowned entrepreneur and investment manager, most notably recognized as the Founder and CEO of Spex Capital. Spex Capital is a venture capital firm specializing in healthtech investments with a primary focus on digital healthcare and med-tech startups. Before establishing Spex Capital, D’Angelo co-founded Ryse Asset Management, a venture that primarily targeted digital health projects. His career spans several top-tier financial institutions where he played significant roles, such as at BNP Paribas and Lehman Brothers. D’Angelo’s contribution to advancing digital healthcare through strategic investments has established him as a key figure in the sector.
Recent Developments
- October 2025: Spex Capital announced a €30 million commitment to its €100 million HealthTech Fund. The fund aims to support early-stage digital health startups globally, offering investments ranging from Seed to Series A/B stages. This initiative is set against a robust backdrop of growing institutional confidence in early-stage health technology, with Spex Capital being a vital player in this space.
- October 2025: Former UK Health Minister Lord Markham was appointed as Chairman of Spex Capital's Board. His leadership is expected to drive groundbreaking startups through the HealthTech Fund, aiming to revolutionize healthcare delivery globally.
- April 2025: Spex Capital continued to expand its influence, emphasizing its strategic partnerships with renowned institutions like EIT Digital and Penn Medicine. These collaborations enhance its capability to source, validate, and scale innovative health technologies.
- 2024: Spex Capital achieved notable success by making early-stage investments in various promising digital health companies aligned with their mission to streamline healthcare systems worldwide.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Claudio D’Angelo |
| Born | Not publicly available |
| Nationality | Italian |
| Occupation | Entrepreneur, Investment Manager |
| Known For | Founder and CEO of Spex Capital |
| Net Worth | Not publicly available |
| Education | Degree in Economics from Bologna University, Executive Master’s in Finance from INSEAD |
Early Life and Education
Claudio D’Angelo pursued his undergraduate studies at the Alma Mater Studiorum – Università di Bologna, obtaining a degree in Economics. He furthered his education with an Executive Master’s in Finance from INSEAD, Fontainebleau, which is renowned for its rigorous management programs. Little is publicly detailed about his early life, but his academic background laid a solid foundation for a successful career in finance and investment. His education reflects a strong inclination towards financial markets and structured investments, equipping him with the necessary skills to navigate the complex world of venture capital.
Career and Notable Achievements
Claudio D’Angelo's professional journey is marked by significant roles in the finance and investment sectors:
- Lehman Brothers (2000-2005): Served as Head of Sales to Europe in Equity Flow, providing him with robust experience in European financial markets.
- BNP Paribas (2005-2009): Held the role of Managing Director, heading Institutional Sales to Europe and the Middle East.
- Gauss Investments Ltd. (2009-2014): Operated as the sole Director.
- Ryse Asset Management (2015-2021): Co-founded this firm, focusing on digital health and med-tech investments.
- Spex Capital (2021-present): Founded this firm, positioning it as a leading early-stage investor in healthtech solutions globally.
Current Work and Impact
Currently, Claudio D'Angelo leads Spex Capital, which he founded in 2021. Under his leadership, the firm has made significant strides in the healthtech investment landscape, focusing particularly on early-stage startups. By leveraging strategic partnerships and investments, Spex Capital addresses critical gaps in healthtech funding, predominantly in Europe. D’Angelo’s work has been instrumental in potentially redefining healthcare systems through innovative digital solutions, thus having a substantial impact on the industry.
Conclusion
Claudio D’Angelo’s significance in the venture capital world, particularly in healthtech, cannot be overstated. Through Spex Capital, he has spearheaded efforts to bridge the innovation and funding gap for health technologies, impacting healthcare delivery systems on a global scale. With noteworthy partnerships and a strategic focus on early-stage investments, D’Angelo is set to continue influencing the healthtech industry, providing solutions that integrate technology with healthcare. His legacy is expected to be one of bridging healthcare innovations and market needs, thereby improving global health systems.